| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 2,347 | 476 | ||
| Marketable securities | 62 | 359 | ||
| Prepaid expenses and other current assets | 166 | 190 | ||
| Total current assets | 2,575 | 1,025 | ||
| Property and equipment, net | 80 | 89 | ||
| Right of use asset, net | 436 | 496 | ||
| Patent and trademark rights, net | 2,041 | 2,168 | ||
| Other assets | 362 | 351 | ||
| Total assets | 5,494 | 4,129 | ||
| Accounts payable | 1,252 | 7,297 | ||
| Accrued expenses | 679 | 573 | ||
| Current portion of operating lease liability | 232 | 233 | ||
| Current portion of note payable, net | 1,880 | 2,290 | ||
| Total current liabilities | 4,043 | 10,393 | ||
| Operating lease liability | 226 | 282 | ||
| Preferred stock, value-Series BConvertible Preferred Stock | - | 0 | ||
| Warrant liability | 7,302 | - | ||
| Preferred stock, value-Series AJunior Participating Preferred Stock | - | 0 | ||
| Total liabilities | 11,571 | 10,675 | ||
| Common stock, 0.001 par value, authorized shares - 350,000,000 issued and outstanding shares 2,764,188 and 655,263 as of september 30, 2025 and december 31, 2024, respectively | 3 | 1 | ||
| Additional paid-in capital | 430,531 | 426,780 | ||
| Accumulated deficit | -436,611 | -433,327 | ||
| Total stockholders equity | -6,077 | -6,546 | ||
| Total liabilities and stockholders equity | 5,494 | 4,129 | ||
AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. (AIM)